2. Antibody-drug Conjugate/ADC Related Apoptosis
  3. Antibody-Drug Conjugates (ADCs) Apoptosis
  4. Zilovertamab vedotin

Zilovertamab vedotin  (Synonyms: VLS-101; MK-2140)

Cat. No.: HY-P99956 Purity: 98.15%
SDS COA

Molarity Calculator

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.

For research use only. We do not sell to patients.

Zilovertamab vedotin Chemical Structure

Zilovertamab vedotin Chemical Structure

Size Price Stock Quantity
1 mg USD 950 In-stock
5 mg USD 2500 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Zilovertamab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer[1].

In Vitro

Zilovertamab vedotin (VLS-101; 0-100 μg/mL) induces cytotoxicity in ROR1+ primary MCL cells in a dose-dependent manner[1].
Zilovertamab vedotin (24h; ibrutinib-sensitive (JeKo-1) and resistant (JeKo BTK KD_2) cell lines) induces cell apoptosis and cell cycle arrest at G2/M[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zilovertamab vedotin Related Antibodies
In Vivo

Zilovertamab vedotin (VLS-101; 2.5 mg/kg; i.v.; weekly, for 3 weeks) targets ROR1-expressing PDX models with dual resistance to ibrutinib and CAR T. A PDX model. Zilovertamab vedotin inhibits tumor growth[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NSG PDX mice models with dual resistance to ibrutinib and CAR T. A PDX model[1]
Dosage: 2.5 mg/kg
Administration: intravenous injection; weekly, for 3 weeks
Result: Eliminated subcutaneous tumor growth of BA-resistant PDX model (PDX-1).
Prolonged tumor bearing mouse survival.
Clinical Trial
Molecular Weight

151000 (average)

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Zilovertamab vedotin]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Zilovertamab vedotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zilovertamab vedotinVLS-101 MK-2140VLS101VLS 101MK2140MK 2140MK-2140Antibody-Drug Conjugates (ADCs)ApoptosisAntibody-Drug ConjugatesZilovertamabanti-microtubule cytotoxin monomethylcancerprimary MCL cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Zilovertamab vedotin
Cat. No.:
HY-P99956
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.